Mid Cap
Drug Manufacturers - General
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Grifois
GRFS
$5.53B
| $5.53B | $8.12 | 0.25% |
|
2
Organon & Co
OGN
$3.62B
| $3.62B | $13.78 | 0.22% |
|
Mid Cap Drug Manufacturers - General Stocks at a Glance
Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.
There are 2 mid cap Drug Manufacturers - General stocks — companies in the Drug Manufacturers - General industry with a market cap between $2B and $10B — worth a combined $9.15B.
The largest by market cap are Grifois (GRFS) at $5.53B and Organon & Co (OGN) at $3.62B.
Among institutional investors, Organon & Co (OGN) drew the most net new fund positions in Q2 2026: 123 funds opened new positions, taking total fund holders up 27 (4.4%) quarter-over-quarter.
- Combined market cap: $9.15B across 2 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: Grifois (GRFS), $5.53B market cap.
- Most net new fund positions in Q2 2026: Organon & Co (OGN), +27 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.